Structure Therapeutics (GPCR) Gains from Investment Securities (2022 - 2026)
Structure Therapeutics (GPCR) recorded quarterly Gains from Investment Securities of $758418.0 in Q1 2026, up 112.89% quarter-over-quarter from -$5.9 million in Q4 2025, and up 2608.64% on a YoY basis from $28000.0 in Q1 2025.
Structure Therapeutics (GPCR) Gains from Investment Securities (2022 - 2026) Analysis & Trends
Structure Therapeutics' Gains from Investment Securities history runs 5 years deep, the most recent figure standing at $758418.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 2608.64% year-over-year to $758418.0; the TTM figure through Mar 2026 stood at $758418.0 (up 2608.64% YoY), while the FY2025 annual figure was $15.4 million, up 21.89% from the prior year.
- Gains from Investment Securities was $758418.0 for Q1 2026 at Structure Therapeutics, up from -$5.9 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $8.3 million in Q3 2023 to a low of -$5.9 million in Q4 2025.
- Historically, Gains from Investment Securities has averaged $1.2 million across 5 years, with a median of $308626.0 in 2023.
- Biggest YoY gain for Gains from Investment Securities was 15309.61% in 2025; the steepest drop was 279.11% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $977000.0 in 2022, then surged by 301.43% to $3.9 million in 2023, then declined by 16.27% to $3.3 million in 2024, then slumped by 279.11% to -$5.9 million in 2025, then soared by 112.89% to $758418.0 in 2026.
- The last three Gains from Investment Securities figures came in at $758418.0 (Q1 2026), -$5.9 million (Q4 2025), and $67794.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Structure Therapeutics | 9.35 Bn | 9.35 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 758,418.00 |
| Mar 31, 2026 | 758,418.00 |
| Dec 31, 2025 | -5.88 Mn |
| Dec 31, 2025 | -5.88 Mn |
| Sep 30, 2025 | 67,794.00 |
| Sep 30, 2025 | 67,794.00 |
| Jun 30, 2025 | 3.97 Mn |
| Jun 30, 2025 | 3.97 Mn |
| Mar 31, 2025 | 28,000.00 |
| Mar 31, 2025 | 28,000.00 |
| Dec 31, 2024 | 3.28 Mn |
| Dec 31, 2024 | 3.28 Mn |
| Sep 30, 2024 | 25,794.00 |
| Sep 30, 2024 | 25,794.00 |
| Jun 30, 2024 | 25,794.00 |
| Jun 30, 2024 | 25,794.00 |
| Mar 31, 2024 | 381,252.00 |
| Mar 31, 2024 | 381,252.00 |
| Dec 31, 2023 | 3.92 Mn |
| Dec 31, 2023 | 3.92 Mn |